Geron
GERN
$3.79
Share price
6.46%
Change (1 day)
59.24%
Change (1 year)
Categories
Geron (GERN) - P/B ratio
P/B ratio as of April 2024 : 9.02
According to Geron's latest financial reports the company has a price-to-book ratio of 9.02.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Geron - P/B ratio (from 2001 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 4.62 | -59.93% |
| 2022-12-31 | 11.5 | 271.18% |
| 2021-12-31 | 3.11 | 32.77% |
| 2020-12-31 | 2.34 | 16.39% |
| 2019-12-31 | 2.01 | 91.72% |
| 2018-12-31 | 1.05 | -62.02% |
| 2017-12-31 | 2.76 | 2.58% |
| 2016-12-31 | 2.69 | -50.22% |
| 2015-12-31 | 5.41 | 38.14% |
| 2014-12-31 | 3.91 | -62.24% |
| 2013-12-31 | 10.4 | 383.46% |
| 2012-12-31 | 2.14 | 61.54% |
| 2011-12-31 | 1.33 | -59.78% |
| 2010-12-31 | 3.30 | 10.92% |
| 2009-12-31 | 2.98 | 35.57% |
| 2008-12-31 | 2.19 | 4.48% |
| 2007-12-31 | 2.10 | -40.94% |
| 2006-12-31 | 3.56 | 11.95% |
| 2005-12-31 | 3.18 | -6.83% |
| 2004-12-31 | 3.41 | -7.51% |
| 2003-12-31 | 3.69 | 22.98% |
| 2002-12-31 | 3.00 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 3.59 | -60.27% | 🇺🇸 USA |
 Incyte INCY | 2.24 | -75.20% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -47.3 | -624.05% | 🇺🇸 USA |
 Bio-Techne TECH | 5.13 | -43.14% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 4.34 | -51.95% | 🇺🇸 USA |